ARGENX SE - ADR (ARGX)
US04016X1019 - ADR
We assign a fundamental rating of 4 out of 10 to ARGX. ARGX was compared to 588 industry peers in the Biotechnology industry. The financial health of ARGX is average, but there are quite some concerns on its profitability. ARGX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ARGX had negative earnings in the past year.
In the past year ARGX has reported a negative cash flow from operations.
ARGX had negative earnings in each of the past 5 years.
ARGX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ARGX has a better Return On Assets (-8.73%) than 89.76% of its industry peers.
ARGX has a Return On Equity of -9.68%. This is amongst the best in the industry. ARGX outperforms 91.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.73% | ||
| ROE | -9.68% | ||
| ROIC | N/A |
ROA(3y)-14.49%
ROA(5y)-16.28%
ROE(3y)-16.18%
ROE(5y)-20.05%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ARGX (90.30%) is better than 93.17% of its industry peers.
The Profit Margin and Operating Margin are not available for ARGX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARGX has more shares outstanding
ARGX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ARGX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 31.87 indicates that ARGX is not in any danger for bankruptcy at the moment.
ARGX has a Altman-Z score of 31.87. This is amongst the best in the industry. ARGX outperforms 95.05% of its industry peers.
ARGX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, ARGX is in line with its industry, outperforming 47.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 31.87 |
ROIC/WACCN/A
WACC7.28%
2.3 Liquidity
ARGX has a Current Ratio of 9.75. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARGX (9.75) is better than 79.52% of its industry peers.
A Quick Ratio of 9.01 indicates that ARGX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.01, ARGX is in the better half of the industry, outperforming 77.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.75 | ||
| Quick Ratio | 9.01 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.82% over the past year.
The Revenue has grown by 210.28% in the past year. This is a very strong growth!
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 120.70% yearly.
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-140%
Revenue 1Y (TTM)210.28%
Revenue growth 3Y209.8%
Revenue growth 5Y120.7%
Revenue growth Q2Q135.99%
3.2 Future
Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 48.09% on average per year.
The Revenue is expected to grow by 34.91% on average over the next years. This is a very strong growth
EPS Next Y52.36%
EPS Next 2Y68.86%
EPS Next 3Y63.56%
EPS Next 5Y48.09%
Revenue Next Year51.49%
Revenue Next 2Y45.32%
Revenue Next 3Y40.22%
Revenue Next 5Y34.91%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ARGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 63.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.86%
EPS Next 3Y63.56%
5. Dividend
5.1 Amount
ARGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARGENX SE - ADR
NASDAQ:ARGX (5/3/2024, 7:00:01 PM)
After market: 388.2 0 (0%)388.2
-5.22 (-1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap23.02B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.73% | ||
| ROE | -9.68% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.3% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.75 | ||
| Quick Ratio | 9.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y52.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)210.28%
Revenue growth 3Y209.8%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y